Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Other Non-Current Liabilities (2024 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Other Non-Current Liabilities for 2 consecutive years, with $5.2 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 186.39% to $5.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.2 million through Dec 2025, up 186.39% year-over-year, with the annual reading at $5.2 million for FY2025, 186.39% up from the prior year.
  • Other Non-Current Liabilities hit $5.2 million in Q4 2025 for Eton Pharmaceuticals, up from $3.9 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $5.2 million in Q4 2025 to a low of $1.8 million in Q4 2024.